In Brief: Circon/U.S. Surgical
This article was originally published in The Gray Sheet
Circon/U.S. Surgical: Circon shareholders elect two USSC-nominated board members to Circon's seven member board of directors in furtherance of USSC's hostile bid to take over the firm, according to a preliminary tabulation of Circon's Oct. 6 shareholder vote by independent inspector of the election Corporation Trust Company. Circon shareholders also appear to have adopted a USSC-sponsored, non-binding resolution to auction Circon to the highest bidder. Circon in late August rejected USSC's most recent tender offer of $16.50 per share, which will expire Oct. 23. USSC's first effort to buy Circon was an $18-per-share bid in August 1996. USSC has filed suit against Circon seeking to enjoin the company from reappointing Chairman and CEO Richard Auhll to the board ("The Gray Sheet" Sept. 22, In Brief)...
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.